MAPT and Alzheimer disease: Together, these findings across two clinical endpoints show that conventional biomarkers reflect susceptibility, whereas proteomic signatures more directly capture the molecular biology of decline, potentially involving networks that drive tau spread, synaptic loss, and metabolic stress, positioning proteomics as a powerful tool for risk stratification and trial enrichment in AD.